amg-232
Small moleculeexperimental
Clinical trial activity
8 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 27, 2012 (NCT01723020)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- E3 ubiquitin-protein ligase Mdm2INHIBITOR
MDM2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
- amg 232
- amg 232
- amg 232
- amg-232
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04190550 | Phase 1 | Aug 14, 2020 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT03217266 | Phase 1 | Nov 3, 2017 | National Cancer Institute (NCI), NRG Oncology |
| NCT03107780 | Phase 1 | Oct 27, 2017 | National Cancer Institute (NCI) |
| NCT03031730 | Phase 1 | Oct 27, 2017 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT03041688 | Phase 1 | Oct 13, 2017 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT02110355 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2014 | Amgen, GlaxoSmithKline |
| NCT02016729 | Phase 1 | Apr 1, 2014 | Amgen |
| NCT01723020 | Phase 1 | Dec 27, 2012 | Amgen |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 5 | 5 | 1 | 2017 |
| Amgen | For profit | 3 | 3 | 2 | 2012 |
| City of Hope National Medical Center | Academic/Hospital | 2 | 0 | 1 | 2017 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2014 |
| NRG Oncology | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2017 |
6 organizations
Page 1 / 1